Size | Price | Stock | Qty |
---|---|---|---|
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
NXY-059 (also known as Cerovive, OKN007, Disufenton Sodium) is a disulfonyl derivative that has shown a significant differences in arterial Po2 and pH between the experimental groups before ischemia in BBB permeability study with Po2 value of 112.9±9.7mm Hg and pH value of 7.443±0.01. In addition, in rats, NXY-059 has been reported to significantly improve neurologic deficits at 24 hours when given at 6 hours of reperfusion. Besides, treatment with NXY-059 has been revealed to significantly ameliorate the brain damage. Thereby, the mean volumes of infarct and total damage are reduced to 9.2±14.8%(P<0.05) and 10.9±15.8%(P<0.01), respectively.
ln Vitro |
|
||
---|---|---|---|
ln Vivo |
|
||
Animal Protocol |
|
||
References |
|
||
Additional Infomation |
Disufenton Sodium is a disulfonyl derivative of phenyl-tert-butyl nitrone (PBN), with potential anti-glioma activity. Although the exact mechanism(s) of action of OKN007 are still largely unknown, this agent appears to inhibit cancer cell proliferation and migration. This agent appears to inhibit the activity of sulfatase 2 (SULF2), a highly specific endoglucosamine-6-sulfatase that is overexpressed in the extracellular matrix of cancer cells and catalyzes the removal of sulfate from the 6-O-sulfate esters of heparin. In addition, OKN007 may induce changes in tumor metabolism and scavenge free radicals.
|
Molecular Formula |
C11H13NNA2O7S2
|
|
---|---|---|
Molecular Weight |
381.33
|
|
Exact Mass |
380.992
|
|
CAS # |
168021-79-2
|
|
Related CAS # |
168021-77-0;168021-79-2 (sodium);
|
|
PubChem CID |
6440181
|
|
Appearance |
White to off-white solid powder
|
|
LogP |
2.907
|
|
Hydrogen Bond Donor Count |
0
|
|
Hydrogen Bond Acceptor Count |
7
|
|
Rotatable Bond Count |
2
|
|
Heavy Atom Count |
23
|
|
Complexity |
578
|
|
Defined Atom Stereocenter Count |
0
|
|
SMILES |
CC(C)(C)/[N+](=C/C1=C(C=C(C=C1)S(=O)(=O)[O-])S(=O)(=O)[O-])/[O-].[Na+].[Na+]
|
|
InChi Key |
XLZOVRYBVCMCGL-BPNVQINPSA-L
|
|
InChi Code |
InChI=1S/C11H15NO7S2.2Na/c1-11(2,3)12(13)7-8-4-5-9(20(14,15)16)6-10(8)21(17,18)19;;/h4-7H,1-3H3,(H,14,15,16)(H,17,18,19);;/q;2*+1/p-2/b12-7-;;
|
|
Chemical Name |
disodium;4-[(Z)-[tert-butyl(oxido)azaniumylidene]methyl]benzene-1,3-disulfonate
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (262.24 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
Solubility in Formulation 2: Saline: 30 mg/mL  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.6224 mL | 13.1120 mL | 26.2240 mL | |
5 mM | 0.5245 mL | 2.6224 mL | 5.2448 mL | |
10 mM | 0.2622 mL | 1.3112 mL | 2.6224 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.